Cerebral vasospasm (CVS) is a frequent and serious neurosurgical complication, without sufficient therapy. This retrospective study was performed to analyze if nimodipine can improve prognosis and reduce ischaemia secondary to delayed CVS after intracranial tumour surgery. A retrospective review was performed over the years 2011 to 2012 for patients with an anterior cranial fossa tumour and underwent intracranial tumour surgery. The surgical field was soaked with nimodipine solution or normal saline. Transcranial Doppler ultrasonography was used to measure velocity in the middle cerebral artery (MCA) and the distal extracranial internal carotid artery (eICA). Follow-up was performed using the Glasgow Outcome Scale (GOS) after discharge. There were 94 patients that met the inclusion criteria. They included 50 males and 44 females, with a mean age of 49.6 years. In the nimodipine group, CVS occurred in 13 patients; 9 patients had CVS between 4 and 7 days, and 4 had CVS between 8 and 14 days. In the normal saline group, 19 patients had CVS, 3 presented with CVS within 3 days, 11 between 4-7 days and 5 between 8-14 days. A significant difference in the occurrence of CVS was observed between the two groups. Preoperative and postoperative the MCA velocities were compared, revealing a significant change in the normal saline group but not in the nimodipine group. Nimodipine markedly improves prognosis and significantly reduces ischaemia secondary to delayed CVS after intracranial tumour surgery, as well as the risks of mortality and morbidity.

• Klíčová slova
• cerebral vasospasm, intracranial tumour surgery, ischaemia, nimodipine,
• MeSH
• arteria cerebri media diagnostické zobrazování   chirurgie   účinky léků   MeSH
• časové faktory MeSH
• dospělí MeSH
• intrakraniální vazospazmus * etiologie   farmakoterapie   diagnostické zobrazování   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory mozku * chirurgie   MeSH
• nimodipin * terapeutické užití   aplikace a dávkování   MeSH
• pooperační komplikace etiologie   prevence a kontrola   MeSH
• retrospektivní studie MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• nimodipin * MeSH

BACKGROUND: Clinically symptomatic vasospasm leading to delayed ischemic neurological deficits occurs in up to 30% of patients with subarachnoid hemorrhage (SAH). Vasospasm can result in a serious decline in clinical conditions of patients with SAH, yet the algorithm for vasospasm treatment and prevention remains unclear. Intra-arterial administration of vasodilators is one of the modalities used for vasospasm therapy. METHODS: Over the last 7 years, we have treated 27 female and 7 male patients with vasospasm using intra-arterial administration of either nimodipine or milrinone; all had suffered aneurysm rupture. Of these patients, 28 were treated surgically (clip), and 6 patients had their aneurysm coiled. Spasmolytics were applied from day 2 to day 18 after rupture. RESULTS: Of the 53 procedures, angiographic improvement was documented in 92% of cases with a mean flow velocity decrease of 65 cm/s. Brain metabolism changes were monitored after the procedure. The highest level of immediate clinical improvement was observed in conscious patients with a focal neurological deficit (aphasia, hemiparesis). Overall clinical outcomes (Glasgow outcome scale, GOS) were as follows: GOS 5 (12 patients), GOS 4 (5 patients), GOS 3 (5 patients), GOS 2 (6 patients), and GOS 1 (6 patients). CONCLUSIONS: Intra-arterial administration of spasmolytics is a safe and potent method of vasospasm treatment. It is most effective when applied to conscious patients with a focal deficit. For unconscious patients, its therapeutic benefits are inconclusive. Patients in severe clinical states would further require use of other diagnostic tools such as multimodal brain monitoring to complement vasospasm therapy.

• Klíčová slova
• Angiography, Cerebral vasospasm, Microdialysis, Milrinone, Nimodipine, Outcome, Spasmolytics, Transcranial dopplerometry,
• MeSH
• angioplastika škodlivé účinky   metody   MeSH
• dospělí MeSH
• intraarteriální infuze škodlivé účinky   MeSH
• intrakraniální vazospazmus farmakoterapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nimodipin aplikace a dávkování   terapeutické užití   MeSH
• subarachnoidální krvácení farmakoterapie   MeSH
• vazodilatancia aplikace a dávkování   terapeutické užití   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• nimodipin MeSH
• vazodilatancia MeSH

Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with the development of early brain injury (EBI) and delayed cerebral ischemia (DCI). Pharmacological treatment of vasospasm following aSAH currently mainly comprises nimodipine administration. In the past few years, many drugs that can potentially benefit cases of subarachnoid hemorrhage have become available. The objective of this review is to critically assess the effects of non-steroidal anti-inflammatory drugs (NSAIDs) following aSAH. A systematic literature review was conducted following PRISMA guidelines. The search was aimed at studies addressing aSAH and NSAIDs during the 2010 to 2019 period, and it yielded 13 articles. Following the application of search criteria, they were divided into two groups, one containing 6 clinical articles and the other containing 7 experimental articles on animal models of aSAH. Inflammatory cerebral changes after aneurysm rupture contribute to the development of EBI, DCI and cerebral vasospasm. It appears that NSAIDs (especially coxibs) are even more effective in reducing vasospasm than nimodipine. Other beneficial effects of NSAIDs include reduction in mortality, improved functional outcome and increased hypoaggregability. However, despite these positive effects, there is only one randomized, double-blind, placebo-controlled trial showing a tendency towards a better outcome with lower incidence of vasospasm or mortality in patients following aSAH.

• Klíčová slova
• Aneurysmal subarachnoid hemorrhage, Cerebral ischemia, Non-steroidal anti-inflammatory drugs, Vasospasms,
• MeSH
• antiflogistika nesteroidní terapeutické užití   MeSH
• dvojitá slepá metoda MeSH
• intrakraniální vazospazmus farmakoterapie   etiologie   patofyziologie   MeSH
• ischemie mozku farmakoterapie   etiologie   patofyziologie   MeSH
• lidé MeSH
• nimodipin terapeutické užití   MeSH
• randomizované kontrolované studie jako téma metody   MeSH
• subarachnoidální krvácení komplikace   farmakoterapie   patofyziologie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• systematický přehled MeSH
• Názvy látek
• antiflogistika nesteroidní MeSH
• nimodipin MeSH

Reversible cerebral vasoconstriction syndrome (RCVS) is characterised by severe thunderclap headaches (with or without the presence of acute neurological symptoms) and segmental vasoconstriction of cerebral arteries that resolves spontaneously in a period of three months. Cases have been described in the literature with producing and non-producing masses of metanephrines. Within these reports, associations with cavernous haemangioma, medulloblastoma, colon cancer, paraganglioma, pheochromocytoma, uterine fibroids, among others were found. However, no association with adrenal masses which do not produce metanephrines was found. In this context, we reported the case of a woman with this type of tumour associated with RCVS which provided a treatment challenge, as well as we reviewed the literature on cases of RCVS associated with masses.

• Klíčová slova
• Cerebral angiography, Headache, Reversible cerebral vasoconstriction syndrome, Tumour,
• MeSH
• intrakraniální vazospazmus * MeSH
• lidé MeSH
• paragangliom * MeSH
• primární bolesti hlavy * MeSH
• vazokonstrikce MeSH
• Check Tag
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH

OBJECTIVE: Ischemic complications account for significant patient morbidity following aneurysmal subarachnoid hemorrhage (aSAH). The Prevention and Treatment of Vasospasm with Clazosentan (REACT) study was designed to assess the safety and efficacy of clazosentan, an endothelin receptor antagonist, in preventing clinical deterioration due to delayed cerebral ischemia (DCI) in patients with aSAH. METHODS: REACT was a prospective, multicenter, randomized, double-blind, phase 3 study. Eligible patients had aSAH secured by surgical clipping or endovascular coiling, and had presented with thick and diffuse clot on admission CT scan. Patients were randomized (1:1 ratio) to 15 mg/hour intravenous clazosentan or placebo within 96 hours of the aSAH for up to 14 days, in addition to standard of care treatment including oral or intravenous nimodipine. The primary efficacy endpoint was the occurrence of clinical deterioration due to DCI up to 14 days after initiation of the study drug. The main secondary endpoint was the occurrence of clinically relevant cerebral infarction at day 16 after study drug initiation. Other secondary endpoints included clinical outcome assessed on the modified Rankin Scale (mRS) and the Glasgow Outcome Scale-Extended (GOSE) at week 12 post-aSAH. Imaging and clinical endpoints were centrally adjudicated. RESULTS: A total of 409 patients were randomized between February 2019 and May 2022 across 74 international sites. Three patients did not start study treatment and were not included in the analysis set. The occurrence of clinical deterioration due to DCI was 15.8% (32/202 patients) in the clazosentan group and 17.2% (35/204 patients) in the placebo group, and the difference was not statistically significant (relative risk reduction [RRR] 7.2%, 95% CI -42.6% to 39.6%, p = 0.734). A nonsignificant RRR of 34.1% (95% CI -21.3% to 64.2%, p = 0.177) was observed in clinically relevant cerebral infarcts treated with clazosentan (7.4%, 15/202) versus placebo (11.3%, 23/204). Rescue therapy was less frequently needed for patients treated with clazosentan compared to placebo (10.4%, 21/202 vs 18.1%, 37/204; RRR 42.6%, 95% CI 5.4%-65.2%). A nonsignificant relative risk increase of 25.4% (95% CI -10.7% to 76.0%, p = 0.198) was reported in the risk of poor GOSE and mRS scores with clazosentan (24.8%, 50/202) versus placebo (20.1%, 41/204) at week 12 post-aSAH. Treatment-emergent adverse events were similar to those reported previously. CONCLUSIONS: Clazosentan administered for up to 14 days at 15 mg/hour had no significant effect on the occurrence of clinical deterioration due to DCI. Clinical trial registration no.: NCT03585270 (ClinicalTrials.gov) EU clinical trial registration no.: 2018-000241-39 (clinicaltrialsregister.eu).

• Klíčová slova
• aneurysm, cerebral ischemia, cerebral vasospasm, clazosentan, endothelin-1, subarachnoid hemorrhage, vascular disorders,
• MeSH
• dioxany * terapeutické užití   škodlivé účinky   MeSH
• dospělí MeSH
• dvojitá slepá metoda MeSH
• intrakraniální vazospazmus etiologie   prevence a kontrola   farmakoterapie   diagnostické zobrazování   MeSH
• ischemie mozku * prevence a kontrola   etiologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• prospektivní studie MeSH
• pyridiny * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• pyrimidiny * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• senioři MeSH
• subarachnoidální krvácení * komplikace   diagnostické zobrazování   MeSH
• sulfonamidy * terapeutické užití   škodlivé účinky   aplikace a dávkování   MeSH
• tetrazoly * terapeutické užití   škodlivé účinky   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• Názvy látek
• clazosentan MeSH Prohlížeč
• dioxany * MeSH
• pyridiny * MeSH
• pyrimidiny * MeSH
• sulfonamidy * MeSH
• tetrazoly * MeSH

OBJECTIVE: The aim of this study was to evaluate the effect of preventive and therapeutic use of subarachnoid sodium nitroprusside (SNP) administration in patients with non-traumatic subarachnoid haemorrhage (SAH). METHODS: All consecutive adult patients admitted in the period 2000-2003 with SAH, Hunt-Hess grade I-IV, indicated for neurosurgical intervention, were enrolled in the study. In the postoperative period they were treated with mechanical ventilation and triple H protocol with nimodipine. Subarachnoid preventive SNP was administred in initial dose of 1 mg by catheter inserted into basal cisterns during the neurosurgical procedure. The timing of following dosage was directed by the changes of respiratory parameters of brain tissue in the region of interest by multiparameter sensor (Codman Neurotrend) and findings of blood flow velocity on the level of circle of Willis were measured by transcranial doppler ultrasonography (TCD). RESULTS: 17 patients were enrolled to study. All patients survived. No brain infarction developed. The increase blood flow velocity was found in three patients. CONCLUSION: Preventive subarachnoid use of SNP in combination with multimodal monitoring might be a possible preventive strategy. Its efficacy has to be proved on a greater group of patients in the future. The therapeutical use of SNP requires an increase in application rate.

• MeSH
• dospělí MeSH
• injekce intraventrikulární MeSH
• intrakraniální vazospazmus diagnóza   etiologie   prevence a kontrola   MeSH
• katetrizace metody   MeSH
• lidé středního věku MeSH
• lidé MeSH
• nitroprusid aplikace a dávkování   MeSH
• senioři MeSH
• subarachnoidální krvácení komplikace   diagnóza   farmakoterapie   MeSH
• subarachnoidální prostor účinky léků   MeSH
• vazodilatancia aplikace a dávkování   MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• Názvy látek
• nitroprusid MeSH
• vazodilatancia MeSH

• MeSH
• dospělí MeSH
• intrakraniální aneurysma komplikace   MeSH
• lidé MeSH
• mozková angiografie MeSH
• retrospektivní studie MeSH
• subarachnoidální krvácení komplikace   MeSH
• tranzitorní ischemická ataka diagnostické zobrazování   etiologie   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: The authors describe two cases of patients with a severe subarachnoid haemorrhage, where mild hypothermia was successfully applied as a part of comprehensive neuroprotective therapy. PATIENTS: A 56-year-old patient was admitted to an intensive care unit with the diagnosis of subarachnoid haemorrhage, with a consciousness dysfunction requiring artificial ventilation. Angiography failed to establish the cause of the haemorrhage, even after repeated examinations. Furthermore, the authors describe the case of a 28-year-old woman with negative anamnesis and without long-term pharmacological medication, who was admitted to the hospital with a severe headache and a qualitative consciousness dysfunction. Angiography showed an aneurysm appearing closely above the left internal carotid artery bifurcation. After detecting vasospasms, mild hypothermia was repeatedly used in both patients, keeping the temperature of the body core between 34-34.5 degrees C. RESULTS: The total length of the introduced therapeutic hypothermia was 12 days in the first case and 6 days in the second case. The method used was non-invasive all-body cooling by means of blankets with circulating cooling liquid (Blanketrol II, Cinncinnati Sub Zero). In both cases the computed tomography findings and the clinical conditions gradually improved and the patients were released from the intensive care unit on the 22nd and 30th day, respectively, following the disorder detection. DISCUSSION: Mild hypothermia is a clinically attainable neuroprotective method, which--in combination with other therapeutic measures--led to minimising the neurological deficit in patients with severe subarachnoid haemorrhage (Ref. 11).

• MeSH
• dospělí MeSH
• intrakraniální vazospazmus etiologie   terapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• subarachnoidální krvácení komplikace   MeSH
• terapeutická hypotermie * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH

The etiology of Transient Global Amnesia (TGA) is not yet clear. A small part of TGA has a familiar occurrence. We report a case of recurrent, long-lasting familiar amnesia occurring after betablocker treatment withdrawal in a migrainous patient. We suggest that familiar TGA could be caused by the mechanism of vasospasm rather than venous congestion and that the abnormal cerebral vasomotor control could be the hereditary substrate in this condition.

• MeSH
• abstinenční syndrom * MeSH
• beta blokátory škodlivé účinky   terapeutické užití   MeSH
• intrakraniální vazospazmus komplikace   MeSH
• lidé středního věku MeSH
• lidé MeSH
• migréna farmakoterapie   MeSH
• recidiva MeSH
• tranzitorní globální amnézie diagnóza   etiologie   MeSH
• vazomotorický systém patofyziologie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• práce podpořená grantem MeSH
• Názvy látek
• beta blokátory MeSH

Transcranial color-coded sonography (TCCS) monitoring of severe brain injury patients may reveal various pathological hemodynamic changes. According to changes in flow velocities in basal brain arteries, the presence of brain hyperemia, vasospasms, and oligemia can be detected. The study included a group of 20 patients with severe brain injury. TCCS measured flow velocities and ICP values were monitored on a daily basis in the course of a week after injury. In nearly 50 % of patients significant hemodynamic changes occurred. The most frequent pathological finding was hyperemia (31.8 %), followed by vasospasm (10.9 %) and oligemia (9.1 %). In 42.7 % of patients increased flow velocities were registered and only 9.1 % of records were within the normal range of values. The most substantial elevation in time-averaged mean velocity occurred from the second to the sixth day after injury. In a subgroup of patients with raised intracranial pressure 41.6 % of flow velocity (FV) measuring met the TCCS criteria for hyperemia compared with 26 % in a subgroup of patients without intracranial pressure (ICP) elevation. The study showed that hemodynamic changes after severe brain injury are relatively common findings and that TCCS is a useful bed-side tool for the monitoring of intracranial hemodynamic changes.

• MeSH
• časové faktory MeSH
• intrakraniální tlak MeSH
• intrakraniální vazospazmus etiologie   MeSH
• klinické kódování MeSH
• lidé MeSH
• mozkový krevní oběh MeSH
• následné studie MeSH
• poranění mozku komplikace   diagnostické zobrazování   MeSH
• rychlost toku krve MeSH
• ultrasonografie dopplerovská transkraniální * MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH